Photogen Commences Phase 1 Study of PH-10 as Treatment for Psoriasis

Apr 25, 2001, 01:00 ET from Photogen Technologies, Inc.

    NEW HOPE, Pa., April 25 /PRNewswire/ -- Photogen Technologies, Inc.
 (Nasdaq:   PHGN) today announced the commencement of a Phase 1 human clinical
 study of its proprietary drug, PH-10, as a topical treatment for psoriasis.
 The study will evaluate the safety of three different doses of PH-10 in
 separate patient treatment groups.  Patients in the study will each receive a
 single dose of PH-10 followed by administration of green light on psoriatic
 plaques.  Each patient will act as his/her own control.
     "We were very encouraged by the interim results of our pilot study
 conducted by Peter Bjerring, M.D., Dr. Sci., of the University of Aarhus,
 Denmark that laid the groundwork for our commencing human clinical studies in
 the United States," said Dr. Taffy Williams, President and Chief Executive
 Officer of Photogen.  "Treatment with PH-10 may provide physicians and
 patients with a significant new means to provide improved clinical management
 of this chronic disease with greatly reduced side effects.  This is the first
 of several potential applications for PH-10 that we intend to study.  Based on
 the probable mechanism of action, PH-10 may also be an appropriate therapy for
 actinic keratosis, a pre-cancerous condition that can lead to skin cancer."
     Psoriasis is a chronic, recurrent disease of the skin.  It typically
 appears as well defined, dry lesions with large silvery scales and marked
 redness.  Its cause is unknown.  According to the National Psoriasis
 Foundation, psoriasis, of which the most common form is plaque psoriasis,
 affects over seven million people in the U.S.  About 150,000 to 260,000 new
 cases are diagnosed annually.  PH-10 is a photodynamic agent that, when
 activated, is believed to selectively reduce inflammation of the epidermis and
 decrease plaque thickness.
 
     Photogen develops innovative therapeutic and diagnostic products using
 proprietary drugs and advanced energy sources.  In addition to the use of
 PH-10 as a treatment for psoriasis, it also shows promise as a treatment for
 other topical disorders and for certain cancer tumors.  The company's cancer
 diagnostic, N1177, being developed through a joint venture with Elan
 Corporation, has completed Phase 1 clinical studies.
 
     Statements in this release that are not strictly historical are "forward -
 looking" statements made pursuant to the safe harbor provisions of the Private
 Securities Litigation Reform Act of 1995.  Forward-looking statements involve
 known and unknown risks that may cause Photogen's actual results in the future
 to differ materially from expected results.  These risks include the ability
 of the company: to develop a product and obtain regulatory approval for its
 use, to obtain necessary financing, and to maintain and defend intellectual
 property protection for its proprietary products.  These and other risks are
 described an qualified in their entirety by cautionary language and risk
 factors set forth in the company's filings from time to time with the
 Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X47197968
 
 

SOURCE Photogen Technologies, Inc.
    NEW HOPE, Pa., April 25 /PRNewswire/ -- Photogen Technologies, Inc.
 (Nasdaq:   PHGN) today announced the commencement of a Phase 1 human clinical
 study of its proprietary drug, PH-10, as a topical treatment for psoriasis.
 The study will evaluate the safety of three different doses of PH-10 in
 separate patient treatment groups.  Patients in the study will each receive a
 single dose of PH-10 followed by administration of green light on psoriatic
 plaques.  Each patient will act as his/her own control.
     "We were very encouraged by the interim results of our pilot study
 conducted by Peter Bjerring, M.D., Dr. Sci., of the University of Aarhus,
 Denmark that laid the groundwork for our commencing human clinical studies in
 the United States," said Dr. Taffy Williams, President and Chief Executive
 Officer of Photogen.  "Treatment with PH-10 may provide physicians and
 patients with a significant new means to provide improved clinical management
 of this chronic disease with greatly reduced side effects.  This is the first
 of several potential applications for PH-10 that we intend to study.  Based on
 the probable mechanism of action, PH-10 may also be an appropriate therapy for
 actinic keratosis, a pre-cancerous condition that can lead to skin cancer."
     Psoriasis is a chronic, recurrent disease of the skin.  It typically
 appears as well defined, dry lesions with large silvery scales and marked
 redness.  Its cause is unknown.  According to the National Psoriasis
 Foundation, psoriasis, of which the most common form is plaque psoriasis,
 affects over seven million people in the U.S.  About 150,000 to 260,000 new
 cases are diagnosed annually.  PH-10 is a photodynamic agent that, when
 activated, is believed to selectively reduce inflammation of the epidermis and
 decrease plaque thickness.
 
     Photogen develops innovative therapeutic and diagnostic products using
 proprietary drugs and advanced energy sources.  In addition to the use of
 PH-10 as a treatment for psoriasis, it also shows promise as a treatment for
 other topical disorders and for certain cancer tumors.  The company's cancer
 diagnostic, N1177, being developed through a joint venture with Elan
 Corporation, has completed Phase 1 clinical studies.
 
     Statements in this release that are not strictly historical are "forward -
 looking" statements made pursuant to the safe harbor provisions of the Private
 Securities Litigation Reform Act of 1995.  Forward-looking statements involve
 known and unknown risks that may cause Photogen's actual results in the future
 to differ materially from expected results.  These risks include the ability
 of the company: to develop a product and obtain regulatory approval for its
 use, to obtain necessary financing, and to maintain and defend intellectual
 property protection for its proprietary products.  These and other risks are
 described an qualified in their entirety by cautionary language and risk
 factors set forth in the company's filings from time to time with the
 Securities and Exchange Commission.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X47197968
 
 SOURCE  Photogen Technologies, Inc.